Surgical Factors Influence the Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an Experienced Center
Authors:
- 3 February 2009
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (4) , 1017-1025
Abstract
Despite a considerable number of randomized studies, the surgical approach to locally advanced adenocarcinoma of the esophagogastric junction (AEG) I and II is still discussed controversially. Thus, we evaluated the surgical risk and outcome after an abdominothoracic esophagectomy (Ivor-Lewis) with intrathoracic anastomosis as standard procedure. Between 1998 and 2006, a total of 240 consecutive patients underwent standardized right thoracoabdominal esophagectomy with two-field lymphadenectomy and intrathoracic anastomosis (Ivor-Lewis operation) for AEG I (n = 206) or AEG II (n = 34). A total of 157 patients (65.4%) had neoadjuvant chemotherapy. Postoperative morbidity occurred in 17.9% (43 of 240). Overall mortality was 3.8% (9 of 240). The majority of patients (4 of 9) died because of severe pulmonary complications (44.4%) irrespective of surgical complications. Neoadjuvant chemotherapy did not increase morbidity or mortality. The median overall survival was 51 months. Multivariate analysis including age >75 years, clinical response to chemotherapy, complications, R-category and N-category revealed R-category (P = .005; relative risk [RR] 0.32, 95% confidence interval [95% CI] 0.14–0.70) and complications (P < .001, RR 0.16, 95% CI 0.08–0.35) as independent prognostic factors for all patients. Complications was the only independent prognostic factor (P < .001, RR 0.09, 95% CI 0.08–0.35) for the R0 resected patients. At an experienced center, Ivor-Lewis resection is a safe surgical procedure. Outcome of patients was significantly influenced by surgical factors such as complete resection and complications. Neoadjuvant chemotherapy did not lead to higher morbidity and mortality. The high mortality from non-surgery–related complications emphasizes the importance of careful preoperative evaluation of comorbidities and patient selection.Keywords
This publication has 53 references indexed in Scilit:
- Paclitaxel in the Neoadjuvant Treatment for Adeno carcinoma of the Distal Esophagus (AEG I). A Comparison of Two Phase II Trials with Long-Term Follow-UpOnkologie, 2008
- Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysisThe Lancet Oncology, 2007
- Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric JunctionJournal of Clinical Oncology, 2006
- Quality of Life After Transhiatal Compared With Extended Transthoracic Resection for Adenocarcinoma of the EsophagusJournal of Clinical Oncology, 2004
- Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II studyGastric Cancer, 2003
- Surgical Approach to Invasive Adenocarcinoma of the Distal Esophagus (Barrett’s Cancer)World Journal of Surgery, 2003
- Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the EsophagusNew England Journal of Medicine, 2002
- Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancerBritish Journal of Surgery, 1998
- Surgical therapy of esophageal carcinoma: the influence of surgical approach and esophageal resection on cardiopulmonary functionEuropean Journal of Cardio-Thoracic Surgery, 1997
- Oesophagectomy by a transhiatal approach or thoracotomy: A prospective randomized trialBritish Journal of Surgery, 1993